课题基金 / 基金详情

项目摘要

项目成果

Tyler J. Curiel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Cancer Development and Progression (CDP) research program, one of the three current and interactive programs of the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA), has evolved from the merging of essential elements of several cancer center programs since the last competitive renewal. The major thematic areas under CDP are: (1) Genomic Integrity, (2) Aging and Cancer, (3) Chronic Inflammation and Cancer, and (4) Women's Cancer. The reorganization reflects some significant changes in the previous program areas, including the departure of several key members and new cancer focuse areas brought to the Center by newly recruited cancer research scientists. The new programmatic structure provides a consolidated platform that is more conducive to collaborative and integrative cancer research. All of the above themes have the potential to develop or re-develop into strong, stand-alone programs in the future, and are expected to do so. The overarching scientific goals of the CDP Program are: (1) to integrate basic research in genomic integrity, age-related cancer susceptibility, tumor microenvironment, and hormone actions and therapeutic resistance in women's cancer to gain a deeper understanding of cancer development and progression; (2) to foster cross-disciplinary collaboration between CDP and the research programs in population studies and experimental and developmental therapeutics; and (3) to translate findings of genetic instability, tumor immunity, obesity/nutrition, and hormone resistance into better cancer prevention and treatment. Currently, the CDP research program has 23 key cancer-focused and funded members and another 25 funded members who conduct cancer-related research that contributes to the understanding of cancer development and progression. Cancer research in the CDP Program receives a total of $7.5 million in peer-reviewed funding (direct), of which $2.4 million is from the NCI (direct). In the current funding period, researchers in the CDP program have made a number of major accomplishments in many areas of cancer biology. These include discoveries of novel factors in double strand DNA break repair, new molecular links between genetic instability and aging, important insight into host-tumor interactions, and molecular interplay of hormone synthesis and actions in breast cancer development. With new cancer research focus, reconfigured interactive programmatic structure, and strong leadership, the CDP Program is well positioned to synergize and integrate further the multi-disciplinary cancer research ongoing in our Cancer Center.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
  • 批准号:
    10467877
  • 项目类别:
  • 资助金额:
    $64.67万
  • 财政年份:
    2022
  • 负责人:
    Tyler J. Curiel
  • 依托单位:
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
  • 批准号:
    10688261
  • 项目类别:
  • 资助金额:
    $62.07万
  • 财政年份:
    2022
  • 负责人:
    Tyler J. Curiel
  • 依托单位:
Regulation of ER-beta Signaling in Carcinogenesis
  • 批准号:
    10092967
  • 项目类别:
  • 资助金额:
    $48.43万
  • 财政年份:
    2019
  • 负责人:
    Tyler J. Curiel
  • 依托单位:
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
海外基金